Peptidomics and Mass Spectrometry

Peptidomics represents the systematic study of all peptides in a biological sample, distinct from proteomics which focuses on larger proteins.

What Is Peptidomics?

Definition The comprehensive study of endogenous peptides: - **Signaling peptides** — Hormones, neuropeptides - **Degradome** — Protein breakdown products - **Processed peptides** — Derived from precursors

Peptide vs. Proteomics Boundary | Feature | Peptidomics | Proteomics | |---------|-------------|------------| | Size range | <10 kDa (<50 AA) | >10 kDa | | Sample prep | No digestion | Tryptic digestion | | Focus | Native peptides | Protein identification | | Complexity | Lower | Higher |

Mass Spectrometry Workflow

Sample Preparation

• Critical first step
• Prevents ex vivo degradation
• Common: acid precipitation, heat inactivation

• Ultrafiltration (10 kDa cutoff)
• Removes large proteins
• Enriches peptide fraction

• Solid-phase extraction
• C18 cartridges
• Removes salts, concentrates sample

LC-MS/MS Analysis

• Reversed-phase C18 columns
• Gradient elution
• Separates peptides by hydrophobicity

• Electrospray ionization (ESI)
• High-resolution mass analyzers
• Orbitrap, Q-TOF instruments

• Fragmentation of peptide ions
• Sequence determination
• Database searching

Identification Challenges

Post-Translational Modifications - Amidation (C-terminal) - Acetylation (N-terminal) - Phosphorylation - Sulfation - Complicate identification

Database Searching - Standard protein databases insufficient - Need peptide-specific databases - Consider alternative cleavages

Quantification - Label-free approaches - Stable isotope labeling - Multiple reaction monitoring (MRM)

The Human Peptidome

Sources of Endogenous Peptides 1. **Prohormone processing** — Insulin, glucagon, etc. 2. **Neuropeptide processing** — Endorphins, neuropeptide Y 3. **Antimicrobial peptides** — Defensins, cathelicidins 4. **Protein degradation** — MHC peptides, degradome

Size Distribution - Peak around 1-3 kDa - Tail to 10 kDa - Majority under 30 amino acids

Applications

Biomarker Discovery - Disease-specific peptide profiles - Cancer markers - Cardiovascular markers - Neurological disease markers

Neuropeptidomics - Brain region-specific analysis - Signaling pathway studies - Drug effect monitoring

Clinical Peptidomics - Urine peptidome (kidney disease) - Plasma peptidome (cardiovascular) - CSF peptidome (neurological)

Drug Development - Target identification - Mechanism of action - Biomarker-guided trials

Technical Advances

High-Resolution MS - Accurate mass determination - Improved identification confidence - Better PTM localization

Data-Independent Acquisition (DIA) - Comprehensive coverage - Improved quantification - SWATH-MS approach

Single-Cell Peptidomics - Individual cell analysis - Heterogeneity studies - Emerging capability